We demonstrate that the genomic mechanisms of ERBB2 activation—inclusive of amplification, mutation, and rare intragenic rearrangements—vary across cancers and that this diverse spectrum of activating alteration types is detectable through CGP of both tissue and liquid biopsies. Here, ERBB2 is linked to cancer.